Trial of abciximab with and without low-dose reteplase for acute myocardial infarction

Circulation

Volumn 101, Issue 24, 2000, Pages 2788-2794

  Ohman, E Magnus ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Fibrinolysis; Myocardial infarction; Platelets; Reperfusion; Trials

Indexed keywords

ABCIXIMAB; HEPARIN; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0343798542     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2788     Document Type: Article

References (19)

1. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755-1759.
2. Nicolini FA, Lee P, Rios G, et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89:1802-1809.
3. Ohman EM, Kleiman NS, Gacioch G, et al. for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein Hb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose-ranging trial. Circulation. 1997;95:846-854.
4. Antman EM, Giugliano RP, Gibson CM, et al, for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-2732.
5. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
6. Bode C, Smalling RW, Berg G, et al, for the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94: 891-988.
7. Martin U, Kohnert U, Stern A, et al. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Thromb Haemost. 1996;76: 1096-1101.
8. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987; 76:142-154.
9. Gibson CM, Cannon CP, Daley WL, et al, for the TIMI-4 Study Group. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
10. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-713.
11. Gore JM, Granger CB, Simoons ML, et al, for the GUSTO-I Investigators. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial. Circulation. 1995;92:2811-2818.
12. The GUSTO-IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
13. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
14. Holmes DR Jr, Bates ER, Kleiman NS, et al, for the GUSTO Investigators. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial. J Am Coll Cardiol. 1995;26:668-674.
15. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation. 1995;92:1883-1890.
16. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
17. Shah A, Wagner GS, Granger CB, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis: reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol. 2000;35: 666-672.
18. The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997; 336:1621-1628. (Erratum. 1997;337:287.)
19. Brener SJ, Barr LA, Burchenal JE, et al, on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-741.